Brachytherapy for clinically localized prostate cancer

✍ Scribed by Haakon Ragde; Leroy Korb

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 100 KB
• Volume: 18
• Category: Article
• ISSN: 8756-0437
• DOI: 10.1002/(sici)1098-2388(200001/02)18:1<45::aid-ssu7>3.0.co;2-1

✦ Synopsis

Prostate brachytherapy is an effective treatment option for clinically organ-confined prostate carcinoma. Observed 5-and 10-year follow-up have documented prostate-specific antigen (PSA) levels that were comparable to published radical prostatectomy series and were better than several published external-beam radiation series. Between January 1987 and June 1988, a total of 152 consecutive patients with Stage T1 to T3 low to high Gleason grade prostate cancer were studied at Northwest Hospital in Seattle, Washington. Patients' median age was 70 years (range, 53 to 92 years). All patients received Iodine-125 prostate brachytherapy with or without a 45 Gy dose of external-beam radiation. The average preoperative PSA, clinical stage, and prostate needle biopsy Gleason sum were 11 ng/ml, T2, and (5), respectively, and were known in all but five patients. PSA follow-up, clinical examination, and biopsy results judged disease-free survival at 5 and 10 postoperative years. Elevation of PSA above 0.5 ng/ ml or a positive biopsy or a positive bone scan was considered treatment failure. The authors provide an historical review of prostate brachytherapy in conjunction with up-to-date implant techniques and long-term outcome results.